Braveheart Bio priced an upsized $382.5 million IPO to fund Phase 3 development of BHB-1893, an oral cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy. The IPO was launched at $18 per share and will begin trading on the Nasdaq Global Market under the ticker BRVE. The company said it intends to use proceeds to advance Phase 3 trials across obstructive HCM and non-obstructive HCM populations, and it highlighted that the therapy is already in late-stage preparation. BHB-1893 was licensed from Jiangsu Hengrui Pharmaceuticals, extending the pattern of China-origin assets reaching US late-stage timelines. The transaction underscores investor appetite for single-asset cardiovascular programs with clear Phase 3 milestones in genetically defined indications, where efficacy readouts can create near-binary valuation inflections.